/
Oncology
Breast Carcinoma
32
Pipeline Programs↗
75
Active Trials↗
24
Companies Involved↗
Breast Carcinoma is a moderately active landscape with 32 programs across 24 companies. The most active players are Puma Biotechnology, Inc., AstraZeneca, Faeth Therapeutics. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Phase 211
Phase 34
Approved
No programs
Analysis
Modality Breakdown
80%
Small molecule
24 of 30 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 94% of 32 pipeline programs.
Analysis
Trial Status
108
clinical trials
Recruiting32 · 30%
Active, not recruiting26 · 24%
Completed21 · 19%
Not yet recruiting16 · 15%
Terminated7 · 6%
Unknown status2 · 2%
Other4 · 4%
Clinical Trials
Trial Activity
108 trials
Electroacupuncture Versus Auricular Acupressure Versus WaitliSt Control for Endocrine Therapy-related Joint Pain in Patients With Breast Cancer (EASE): A Pragmatic Multicenter Randomised Controlled Trial
Recruiting·First Teaching Hospital of Tianjin University of Traditional Chinese Medicine·Preclinical·NCT07490938·200 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)